Analyst Price Target is $2.00
▲ +399.75% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Lipella Pharmaceuticals in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 399.75% upside from the last price of $0.40.
Current Consensus is
Buy
The current consensus among 1 investment analysts is to buy stock in Lipella Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Read More